Logo image of QLI

QILIAN INTERNATIONAL HOLDING (QLI) Stock Fundamental Analysis

USA - NASDAQ:QLI - KYG7307E1237 - Common Stock

5.41 USD
-0.35 (-6.08%)
Last: 8/9/2024, 8:09:24 PM
Fundamental Rating

3

QLI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While QLI seems to be doing ok healthwise, there are quite some concerns on its profitability. QLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

QLI had negative earnings in the past year.
In the past year QLI had a positive cash flow from operations.
QLI had positive earnings in 4 of the past 5 years.
Of the past 5 years QLI 4 years had a positive operating cash flow.
QLI Yearly Net Income VS EBIT VS OCF VS FCFQLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

1.2 Ratios

QLI has a better Return On Assets (-15.18%) than 66.84% of its industry peers.
Looking at the Return On Equity, with a value of -18.18%, QLI is in the better half of the industry, outperforming 74.09% of the companies in the same industry.
Industry RankSector Rank
ROA -15.18%
ROE -18.18%
ROIC N/A
ROA(3y)-3.11%
ROA(5y)3.26%
ROE(3y)-3.47%
ROE(5y)7.16%
ROIC(3y)N/A
ROIC(5y)N/A
QLI Yearly ROA, ROE, ROICQLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

1.3 Margins

QLI has a Gross Margin (3.77%) which is in line with its industry peers.
In the last couple of years the Gross Margin of QLI has declined.
The Profit Margin and Operating Margin are not available for QLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37%
GM growth 5Y-25.24%
QLI Yearly Profit, Operating, Gross MarginsQLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

6

2. Health

2.1 Basic Checks

QLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
QLI has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, QLI has less shares outstanding
The debt/assets ratio for QLI has been reduced compared to a year ago.
QLI Yearly Shares OutstandingQLI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
QLI Yearly Total Debt VS Total AssetsQLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

QLI has an Altman-Z score of 4.38. This indicates that QLI is financially healthy and has little risk of bankruptcy at the moment.
QLI's Altman-Z score of 4.38 is fine compared to the rest of the industry. QLI outperforms 78.76% of its industry peers.
QLI has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
QLI has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 4.38
ROIC/WACCN/A
WACC8.08%
QLI Yearly LT Debt VS Equity VS FCFQLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M 20M 30M 40M 50M

2.3 Liquidity

A Current Ratio of 5.18 indicates that QLI has no problem at all paying its short term obligations.
QLI has a better Current ratio (5.18) than 61.66% of its industry peers.
QLI has a Quick Ratio of 4.43. This indicates that QLI is financially healthy and has no problem in meeting its short term obligations.
QLI has a Quick ratio of 4.43. This is comparable to the rest of the industry: QLI outperforms 58.55% of its industry peers.
Industry RankSector Rank
Current Ratio 5.18
Quick Ratio 4.43
QLI Yearly Current Assets VS Current LiabilitesQLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

0

3. Growth

3.1 Past

QLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3727.33%.
Looking at the last year, QLI shows a very negative growth in Revenue. The Revenue has decreased by -28.35% in the last year.
Measured over the past years, QLI shows a decrease in Revenue. The Revenue has been decreasing by -1.60% on average per year.
EPS 1Y (TTM)-3727.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3958.33%
Revenue 1Y (TTM)-28.35%
Revenue growth 3Y-2.43%
Revenue growth 5Y-1.6%
Sales Q2Q%-47.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QLI Yearly Revenue VS EstimatesQLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QLI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QLI Price Earnings VS Forward Price EarningsQLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QLI Per share dataQLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

QLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

QILIAN INTERNATIONAL HOLDING

NASDAQ:QLI (8/9/2024, 8:09:24 PM)

5.41

-0.35 (-6.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-09 2024-02-09
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap38.68M
Revenue(TTM)46.47M
Net Income(TTM)-7.78M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-22.97%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.83
P/FCF N/A
P/OCF 123.9
P/B 0.9
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.04
OCFY0.81%
SpS6.5
BVpS5.98
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.18%
ROE -18.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.77%
FCFM N/A
ROA(3y)-3.11%
ROA(5y)3.26%
ROE(3y)-3.47%
ROE(5y)7.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37%
GM growth 5Y-25.24%
F-Score4
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 178.92%
Cap/Sales 4.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.18
Quick Ratio 4.43
Altman-Z 4.38
F-Score4
WACC8.08%
ROIC/WACCN/A
Cap/Depr(3y)245.66%
Cap/Depr(5y)166.1%
Cap/Sales(3y)5.18%
Cap/Sales(5y)3.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3727.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3958.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.35%
Revenue growth 3Y-2.43%
Revenue growth 5Y-1.6%
Sales Q2Q%-47.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-224.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-118.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-97.53%
OCF growth 3Y-60.54%
OCF growth 5Y-41.2%

QILIAN INTERNATIONAL HOLDING / QLI FAQ

What is the ChartMill fundamental rating of QILIAN INTERNATIONAL HOLDING (QLI) stock?

ChartMill assigns a fundamental rating of 3 / 10 to QLI.


What is the valuation status of QILIAN INTERNATIONAL HOLDING (QLI) stock?

ChartMill assigns a valuation rating of 0 / 10 to QILIAN INTERNATIONAL HOLDING (QLI). This can be considered as Overvalued.


What is the profitability of QLI stock?

QILIAN INTERNATIONAL HOLDING (QLI) has a profitability rating of 3 / 10.